Trade Globus Medical, Inc. - GMED CFD

Add to favourite

50.28

0.79%

0.17

Low: 49.94

High: 50.88

Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.17

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Globus Medical Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	50.68
Open*	50.88
1-Year Change*	-11.62%
Day's Range*	49.94 - 50.88
52 wk Range	43.39-80.04
Average Volume (10 days)	1.61M
Average Volume (3 months)	26.34M
Market Cap	7.68B
P/E Ratio	36.03
Shares Outstanding	137.79M
Revenue	1.23B
EPS	1.55
Dividend (Yield %)	N/A
Beta	1.10
Next Earnings Date	Feb 19, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 19, 2024	50.28	-0.14	-0.28%	50.42	50.98	49.78
Apr 18, 2024	50.68	-0.10	-0.20%	50.78	51.42	50.49
Apr 17, 2024	51.01	-0.68	-1.32%	51.69	51.82	50.96
Apr 16, 2024	51.70	0.90	1.77%	50.80	51.96	50.60
Apr 15, 2024	51.61	-0.15	-0.29%	51.76	52.62	51.39
Apr 12, 2024	51.60	-0.05	-0.10%	51.65	52.16	51.16
Apr 11, 2024	52.39	-1.14	-2.13%	53.53	53.78	52.13
Apr 10, 2024	53.04	0.76	1.45%	52.28	53.17	52.28
Apr 9, 2024	53.58	0.60	1.13%	52.98	53.65	52.76
Apr 8, 2024	53.11	1.16	2.23%	51.95	53.31	51.50
Apr 5, 2024	51.58	0.68	1.34%	50.90	51.80	50.51
Apr 4, 2024	51.12	-0.89	-1.71%	52.01	52.79	50.97
Apr 3, 2024	50.29	-0.79	-1.55%	51.08	52.59	50.28
Apr 2, 2024	51.76	-0.24	-0.46%	52.00	52.26	51.37
Apr 1, 2024	52.94	-0.31	-0.58%	53.25	53.89	52.37
Mar 28, 2024	53.42	0.93	1.77%	52.49	53.91	52.49
Mar 27, 2024	52.82	1.28	2.48%	51.54	53.19	51.23
Mar 26, 2024	51.55	0.40	0.78%	51.15	51.79	50.78
Mar 25, 2024	51.09	-0.57	-1.10%	51.66	52.18	50.73
Mar 22, 2024	51.75	0.00	0.00%	51.75	52.66	51.43

Globus Medical, Inc. Events

Time (UTC)	Country	Event
Thursday, May 2, 2024
Time (UTC) 10:59	Country US	Event Q1 2024 Globus Medical Inc Earnings Release Q1 2024 Globus Medical Inc Earnings Release Forecast - Previous -
Thursday, June 6, 2024
Time (UTC) 22:00	Country US	Event Globus Medical Inc Annual Shareholders Meeting Globus Medical Inc Annual Shareholders Meeting Forecast - Previous -
Thursday, August 1, 2024
Time (UTC) 10:59	Country US	Event Q2 2024 Globus Medical Inc Earnings Release Q2 2024 Globus Medical Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	1022.84	958.102	789.042	785.368	712.969
Revenue	1022.84	958.102	789.042	785.368	712.969
Cost of Revenue, Total	263.725	239.223	217.463	179.975	159.41
Gross Profit	759.118	718.879	571.579	605.393	553.559
Total Operating Expense	794.892	786.149	677.609	613.379	543.644
Selling/General/Admin. Expenses, Total	432.117	408.149	354.757	354.757	311.591
Research & Development	73.015	97.346	84.519	60.073	55.496
Depreciation / Amortization	17.735	18.526	16.831	13.809	9.588
Unusual Expense (Income)	8.3	22.905	4.039	4.765	7.559
Operating Income	227.951	171.953	111.433	171.989	169.325
Interest Income (Expense), Net Non-Operating	13.213	7.874	13.673	17.481	13.638
Other, Net	1.855	0.58	0.793	0.476	5.642
Net Income Before Taxes	243.019	180.407	125.899	189.946	188.605
Net Income After Taxes	190.169	149.191	102.285	155.21	156.474
Net Income Before Extra. Items	190.169	149.191	102.285	155.21	156.474
Net Income	190.169	149.191	102.285	155.21	156.474
Income Available to Common Excl. Extra. Items	190.169	149.191	102.285	155.21	156.474
Income Available to Common Incl. Extra. Items	190.169	149.191	102.285	155.21	156.474
Diluted Net Income	190.169	149.191	102.285	155.21	156.474
Diluted Weighted Average Shares	102.643	103.623	100.971	101.998	101.316
Diluted EPS Excluding Extraordinary Items	1.85272	1.43975	1.01301	1.5217	1.54442
Diluted Normalized EPS	1.916	1.62254	1.04551	1.55987	1.60631
Total Extraordinary Items

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	291.615	276.688	274.498	254.148	263.648
Revenue	291.615	276.688	274.498	254.148	263.648
Cost of Revenue, Total	76.473	70.825	70.591	65.497	68.47
Gross Profit	215.142	205.863	203.907	188.651	195.178
Total Operating Expense	225.403	220.285	220.47	194.446	195.872
Selling/General/Admin. Expenses, Total	120.069	122.416	118.075	106.576	106.718
Research & Development	21.347	21.082	19.507	18.701	17.395
Depreciation / Amortization	4.547	4.601	4.506	4.324	4.393
Unusual Expense (Income)	2.967	1.361	7.791	-0.652	-1.104
Operating Income	66.212	56.403	54.028	59.702	67.776
Interest Income (Expense), Net Non-Operating	7.746	6.709	8.003	1.689	1.369
Other, Net	0.716	0.077	0.085	0.074	1.395
Net Income Before Taxes	74.674	63.189	62.116	61.465	70.54
Net Income After Taxes	57.712	49.129	50.065	47.431	54.59
Net Income Before Extra. Items	57.712	49.129	50.065	47.431	54.59
Net Income	57.712	49.129	50.065	47.431	54.59
Income Available to Common Excl. Extra. Items	57.712	49.129	50.065	47.431	54.59
Income Available to Common Incl. Extra. Items	57.712	49.129	50.065	47.431	54.59
Diluted Net Income	57.712	49.129	50.065	47.431	54.59
Diluted Weighted Average Shares	101.782	102.196	102.205	99.652	102.884
Diluted EPS Excluding Extraordinary Items	0.56702	0.48073	0.48985	0.47597	0.5306
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	0.58954	0.49109	0.55129	0.47092	0.52229

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	983.344	864.516	821.765	687.468	630.681
Cash and Short Term Investments	446.058	443.447	426.741	311.487	339.684
Cash & Equivalents	150.466	193.069	239.397	195.724	139.747
Short Term Investments	295.592	250.378	187.344	115.763	199.937
Total Receivables, Net	217.308	165.651	148.1	162.424	144.356
Accounts Receivable - Trade, Net	213.247	164.436	141.676	154.326	137.067
Total Inventory	298.981	237.001	229.153	196.314	131.254
Prepaid Expenses	20.997	18.417	17.771	17.243	15.387
Other Current Assets, Total
Total Assets	2076.13	1957.26	1679.48	1532.08	1300.67
Property/Plant/Equipment, Total - Net	243.729	226.095	221.62	202.322	171.873
Property/Plant/Equipment, Total - Gross	586.765	531.67	498.071	446.054	388.682
Accumulated Depreciation, Total	-343.036	-305.575	-276.451	-243.732	-216.809
Goodwill, Net	197.471	179.708	156.716	128.775	123.734
Intangibles, Net	63.574	68.66	86.949	78.812	87.323
Long Term Investments	495.852	562.475	358.522	409.514	263.117
Note Receivable - Long Term					0
Other Long Term Assets, Total	92.156	55.809	33.913	25.186	23.942
Total Current Liabilities	159.204	140.164	120.792	111.403	96.118
Accounts Payable	36.101	21.955	18.205	24.614	25.895
Accrued Expenses	94.705	91.168	78.334	63.283	59.878
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	28.398	27.041	24.253	23.506	10.345
Total Liabilities	229.753	215.875	173.188	129.625	115.154
Total Long Term Debt	0	0	0	0	0
Deferred Income Tax	1.779	4.314	6.202	6.023	8.114
Other Liabilities, Total	68.77	71.397	46.194	12.199	10.922
Total Equity	1846.37	1741.39	1506.3	1402.45	1185.52
Common Stock	0.1	0.101	0.099	0.099	0.098
Additional Paid-In Capital	630.952	553.787	457.161	357.32	299.869
Retained Earnings (Accumulated Deficit)	1239.95	1194.27	1045.08	1047.93	892.721
Unrealized Gain (Loss)	-15.093	-1.053	5.001	3.599	-0.168
Other Equity, Total	-9.537	-5.719	-1.046	-6.497	-7.004
Total Liabilities & Shareholders’ Equity	2076.13	1957.26	1679.48	1532.08	1300.67
Total Common Shares Outstanding	100.192	101.544	99.7141	99.825	98.573

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	1917.34	1210.01	1070.43	983.344	920.001
Cash and Short Term Investments	468.934	612.828	504.37	446.058	405.286
Cash & Equivalents	279.62	306.452	217.685	150.466	134.223
Short Term Investments	189.314	306.376	286.685	295.592	271.063
Total Receivables, Net	495.852	241.942	225.825	217.308	208.504
Accounts Receivable - Trade, Net	494.112	240.184	222.783	213.247	206.307
Total Inventory	904.977	335.556	321.033	298.981	282.408
Prepaid Expenses	47.574	19.684	19.201	20.997	23.803
Total Assets	5355.88	2212.47	2149.62	2076.13	1976.51
Property/Plant/Equipment, Total - Net	703.051	248.048	245.098	243.729	236.342
Property/Plant/Equipment, Total - Gross	1090.87	612.263	598.966	586.765	569.259
Accumulated Depreciation, Total	-387.816	-364.215	-353.868	-343.036	-332.917
Goodwill, Net	1122.43	198.932	198.71	197.471	181.774
Intangibles, Net	1261.62	54.901	59.194	63.574	54.057
Long Term Investments	275.958	391.521	480.025	495.852	503.965
Other Long Term Assets, Total	75.484	109.053	96.164	92.156	80.373
Total Current Liabilities	428.722	155.22	167.547	159.204	145.255
Accounts Payable	86.934	33.811	39.835	36.101	31.971
Accrued Expenses	234.431	89.606	83.998	94.705	88.361
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	106.733	31.803	43.714	28.398	24.923
Total Liabilities	1168.59	227.4	234.8	229.753	212.401
Total Long Term Debt	410.392	0	0	0	0
Deferred Income Tax	132.191	5.299	1.369	1.779	1.578
Other Liabilities, Total	197.285	66.881	65.884	68.77	65.568
Total Equity	4187.29	1985.06	1914.82	1846.37	1764.11
Common Stock	0.14	0.1	0.1	0.1	0.099
Additional Paid-In Capital	2858.09	657.24	645.062	630.952	606.352
Retained Earnings (Accumulated Deficit)	1347.79	1346.79	1289.08	1239.95	1189.89
Unrealized Gain (Loss)	-8.114	-10.755	-10.795	-15.093	-19.292
Other Equity, Total	-10.622	-8.312	-8.627	-9.537	-12.934
Total Liabilities & Shareholders’ Equity	5355.88	2212.47	2149.62	2076.13	1976.51
Total Common Shares Outstanding	140.6	100.443	100.335	100.192	99.8316
Current Port. of LT Debt/Capital Leases	0.624
Long Term Debt	409.723
Capital Lease Obligations	0.669

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	190.169	149.191	102.285	155.21	156.474
Cash From Operating Activities	178.468	276.274	198.793	171.975	181.643
Cash From Operating Activities	68.252	69.867	62.874	52.734	41.63
Deferred Taxes	-22.223	-17.615	-4.338	4.302	0.971
Non-Cash Items	47.532	92.083	75.562	33.173	32.436
Cash Taxes Paid	77.823	45.027	25.437	34.139	30.552
Cash Interest Paid				0.079	0.006
Changes in Working Capital	-105.262	-17.252	-37.59	-73.444	-49.868
Cash From Investing Activities	-110.362	-375.939	-117.322	-140.281	-193.027
Capital Expenditures	-74.047	-56.898	-63.658	-70.75	-59.697
Other Investing Cash Flow Items, Total	-36.315	-319.041	-53.664	-69.531	-133.33
Cash From Financing Activities	-109.962	54.147	-38.663	24.439	32.57
Financing Cash Flow Items	-7.185	-9.349	-6.316	-6.597	-6.739
Issuance (Retirement) of Stock, Net	-102.777	63.496	-32.347	31.036	39.309
Foreign Exchange Effects	-0.747	-0.81	0.865	-0.156	-0.256
Net Change in Cash	-42.603	-46.328	43.673	55.977	20.93

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	49.129	190.169	140.104	92.674	38.084
Cash From Operating Activities	53.313	178.468	114.493	81.573	44.69
Cash From Operating Activities	18.108	68.252	51.342	33.764	16.837
Deferred Taxes	-3.979	-22.223	-17.014	-7.939	-2.994
Non-Cash Items	11.163	47.532	30.42	20.448	10.057
Cash Taxes Paid	1.724	77.823	58.301	-36.696	0.572
Changes in Working Capital	-21.108	-105.262	-90.359	-57.374	-17.294
Cash From Investing Activities	10.992	-110.362	-49.878	13.232	-13.894
Capital Expenditures	-15.991	-74.047	-55.707	-43.724	-19.971
Other Investing Cash Flow Items, Total	26.983	-36.315	5.829	56.956	6.077
Cash From Financing Activities	2.94	-109.962	-123.553	-136.715	6.047
Financing Cash Flow Items	-1.919	-7.185	-5.288	-3.553	-1.699
Issuance (Retirement) of Stock, Net	4.859	-102.777	-118.265	-133.162	7.746
Foreign Exchange Effects	-0.026	-0.747	0.092	-0.387	-0.123
Net Change in Cash	67.219	-42.603	-58.846	-42.297	36.72

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Globus Medical, Inc. Company profile

About Globus Medical Inc

Globus Medical, Inc. is a medical device company. The Company is primarily focused on implants that promote healing in patients with musculoskeletal disorders. The Company group its products into two categories: Musculoskeletal Solutions and Enabling Technologies. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in an expansive range of spinal, orthopedic and neurosurgical procedures. Its Enabling Technologies are comprised of imaging, navigation and robotics (INR) solutions for assisted surgery, which are computer-assisted intelligent systems designed to improve a surgeon’s capabilities, and ultimately improve patient care and reduce radiation exposure for all involved. Its INR solutions include the ExcelsiusGPS platform, which is a robotic guidance and navigation system that supports minimally invasive and open procedures with screw and interbody spacer placement applications.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Globus Medical Inc revenues increased 21% to $958.1M. Net income increased 46% to $149.2M. Revenues reflect Musculoskeletal Solutions products segment increase of 17% to $876.8M, Enabling Technologies products segment increase of 100% to $81.3M, United States segment increase of 23% to $819.6M, International segment increase of 11% to $138.5M.

Equity composition

Cls A Common stock $.001 Par 8/12, 500M auth., 62,503,441 issd., Insiders own approx. 86.70%. Cls B Common Stock 275M auth., 27,885,000 issd.

Industry:

Medical Equipment, Supplies & Distribution (NEC)

2560 General Armistead Ave
AUDUBON
PENNSYLVANIA 19403
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024